공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

대장암(CRC) : 역학 예측

Colorectal Cancer: Epidemiology Forecast to 2028

리서치사 GlobalData
발행일 2019년 11월 상품 코드 918520
페이지 정보 영문 47 Pages
가격
US $ 3,995 ₩ 4,457,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 8,914,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 13,371,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


대장암(CRC) : 역학 예측 Colorectal Cancer: Epidemiology Forecast to 2028
발행일 : 2019년 11월 페이지 정보 : 영문 47 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 8개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본, 중국)에서 대장암(CRC)으로 진단된 발증 건수는 2018년 82만 7,242건에서 2028년 107만 8,959건으로 AGR(연간 성장률)로 3.04%의 증가가 예측됩니다.

세계 주요 8개국의 대장암(CRC) 시장에 대해 조사 분석했으며, 최신 역학 예측에 대한 체계적인 정보를 제공합니다.

제1장 목차

제2장 주요 요약

제3장 역학

  • 질환 배경
  • 위험인자와 병존 질환
  • 세계의 동향과 과거 동향
  • 예측 방법
  • 대장암(CRC) 역학 예측
  • 논의

제4장 부록

KSM 19.12.24

List of Tables

  • Table 1: Risk Factors and Comorbid Conditions Associated with CRC
  • Table 2: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ≥18 Years, 2018
  • Table 3: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2019

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018 and 2028
  • Figure 3: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ≥18 Years, 2018-2028
  • Figure 4: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ≥18 Years, 2018-2028
  • Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC
  • Figure 6: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC
  • Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness
  • Figure 11: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ≥18 Years, 2018
  • Figure 12: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 13: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ≥18 Years, 2018
  • Figure 14: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 15: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 16: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 18: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018

Colorectal cancer (CRC) is a cancer that occurs in the large intestine or large bowel (Centers for Disease Control and Prevention, 2019). Most CRCs start as abnormal growths known as polyps on the inner lining of the colon or rectum. Over time, some polyps may turn into cancer (American Cancer Society, 2018). Common symptoms of CRC are: blood in stool, stomach pain, aches or cramps that do not go away, weight loss, and a persistent change in bowel habit. CRC screening tests help to find colorectal cancer at an early stage and/or remove pre-cancerous polyps in the colon or rectum (American Cancer Society, 2018).

GlobalData epidemiologists utilized country-specific cancer registries, national databases, and robust peer-reviewed journal articles to build the forecast for the diagnosed incident cases and diagnosed prevalent cases of CRC in the 8MM.

The following data describes epidemiology of CRC. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CRC in the 8MM, from 827,242 cases in 2018 to 1,078,959 cases in 2028 at an AGR of 3.04% during the forecast period. The diagnosed prevalent cases of CRC in the 8MM are also expected to increase, from 5,307,305 cases in 2018 to 7,303,381 cases in 2028, at an AGR of 3.76% over the forecast period. CRC is more common in men than women and the risk of developing CRC increases with age. These trends are reflected in GlobalData's forecast for the diagnosed incident cases, with older age groups (ages ≥65 years) contributing the highest proportion of the incident cases in the 8MM.

Scope

  • The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CRC segmented by sex, and age (ages ≥18 years) in these markets. - The diagnosed incident cases of CRC are further segmented by stage at diagnosis (stage I, II, III, and IV), by type of molecular markers (KRAS, NRAS, MET amplification, MSI-dMMR, HER2 amplification, NTRK gene fusion, and BRAF V600E), and sidedness (right-sided and left-sided). The report also includes diagnosed incident cases of CRC by population with curable synchronous liver metastases, five-year diagnosed prevalent cases of CRC, and all-time diagnosed prevalent cases of CRC.
  • The colorectal cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Colorectal Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global colorectal cancer market.
  • Quantify patient populations in the global colorectal cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for colorectal cancer therapeutics in each of the markets covered.
  • Understand magnitude of colorectal cancer population by stage at diagnosis.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Colorectal Cancer: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for CRC (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of CRC
    • 3.5.2 Age-Specific Diagnosed Incident Cases of CRC
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of CRC
    • 3.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of CRC by Molecular Markers
    • 3.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis
    • 3.5.7 Diagnosed Incident Cases of CRC by Sidedness
    • 3.5.8 Five-Year Diagnosed Prevalent Cases of CRC
    • 3.5.9 All-Time Diagnosed Prevalent Cases of CRC
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer
Back to Top
전화 문의
F A Q